Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online March 2, 2017.
Article Versions
- You are currently viewing a previous version of this article (March 2, 2017 - 05:04).
- View the most recent version of this article
Copyright & Usage
Copyright © 2017 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Jörg Schulz1,
- Martin Rohracker1,
- Marvin Stiebler1,
- Jürgen Goldschmidt2,
- Franziska Stöber2,
- Mercedes Noriega3,
- Anette Pethe1,
- Mathias Lukas4,
- Frank Osterkamp5,
- Ulrich Reineke5,
- Aileen Höhne5,
- Christiane Smerling5 and
- Holger Amthauer4
- 1 Otto-von-Guericke Universität Magdeburg, Germany;
- 2 Leibniz-Institut für Neurobiologie, Magdeburg, Germany;
- 3 Universitätsklinik Hamburg-Eppendorf, Germany;
- 4 Charité - Universitätsmedizin Berlin, Germany;
- 5 3B Pharmaceuticals GmbH, Germany
- For correspondence or reprints contact: Holger Amthauer, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin 13353, Germany. E-mail: holger.amthauer@charite.de
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Synthesis of 64Cu-, 55Co-, and 68Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles
- Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism
- Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted {alpha}-particle therapy
- Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review
- Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- 177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results
- NTR Is the New SSTR? Perspective for Neurotensin Receptor 1 (NTR)-Directed Theranostics